Peptide

CJC-1295 with DAC

Also known as

CJC-1295 DAC · CJC DAC · Drug Affinity Complex CJC · DAC:GRF · DAC-GRF · CJC-1295 (with DAC) · long-acting CJC-1295 · CJC1295 DAC · CJC-1295 · albumin-binding CJC-1295 · ConjuChem DAC:GRF

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Long-acting GH-release signal	A peptide that signals the pituitary to release growth hormone. Its Drug Affinity Complex (DAC) binds blood albumin and prolongs exposure, with downstream IGF-1 changes.
DAC versus no-DAC	Community CJC shorthand can mean short-acting Mod GRF 1–29. Daily CJC/Ipamorelin blends often mean no-DAC; their amounts are not interchangeable with weekly DAC milligrams.

Notes

A longer-lasting signal to release growth hormone. CJC mimics growth-hormone-releasing hormone, which signals the pituitary to release GH; GH influences downstream IGF-1. DAC means Drug Affinity Complex, an attachment that binds albumin in blood and prolongs exposure. This is systemic hormone-axis stimulation, not local tendon repair. Ionescu and Frohman 2006: GH pulsatility during CJC-1295 exposure (Official context · Accessed 2026-09-30)

The name alone can hide two different products. Papers generally mean the long-acting DAC form. Community shorthand also calls short-acting Mod GRF 1–29 “CJC-1295.” Daily CJC/Ipamorelin blends frequently mean no-DAC. The preserved discussion describes mostly subcutaneous injections, occasional intramuscular claims and no dependable oral equivalent; none is interchangeable by milligram arithmetic.

Source context — Ionescu and Frohman 2006: GH pulsatility during CJC-1295 exposure: Abstract-only access; narrow population and one-week hormone sampling cannot establish long-term outcomes.

What people notice

Sleep and recovery	One user reported better sleep after two nights; another at week three still had no noticeable muscle gain or major fat loss while using several peptides.
Fewer injections, mixed physique change	Convenience, less soreness and a fuller look drive interest. Water retention can imitate muscle fullness, while fatigue and stiff hands can dominate the experience.

Notes

Sleep is a reported benefit; physique change is less immediate. One Reddit user described better sleep after two nights. Another, using DAC with Ipamorelin and injury peptides, reported better sleep at week three but no noticeable muscle gain or major fat loss. Neither account isolates DAC or predicts someone else's response. CJC-1295 DAC: first-dose and sleep experiences (Community discussion · Accessed 2026-09-30) · CJC 1295 DAC: low-dose book claim and week-three update (Community discussion · Accessed 2026-09-30)

Recovery and convenience drive the interest. Community accounts seek less soreness, easier training, lean-mass support, skin changes or a fuller look over weeks to months. Fewer injections matter to users tired of short-acting stacks. Water weight can imitate muscle fullness; these outcomes remain reports rather than demonstrated DAC benefits. CJC 1295 DAC: low-dose book claim and week-three update (Community discussion · Accessed 2026-09-30)

Fluid retention, stiff hands and fatigue deserve their own attention. Swelling, ring tightness, numbness and joint aches can obscure perceived physique gains. An opened bodybuilding-forum user found lethargy disruptive despite believing they were leaning out; testosterone use confounded that account. Bedtime administration was not a demonstrated solution. CJC-1295 DAC half-life/sides (Personal report · Accessed 2026-09-30) · CJC 1295 dac and lethargy (Personal report · Accessed 2026-09-30)

Source context — CJC-1295 DAC: first-dose and sleep experiences: Different authors; short follow-up, some deleted identities, unverified contents; relative timestamps not converted to exact dates.

Source context — CJC 1295 DAC: low-dose book claim and week-three update: Book not directly inspected; OP initial proposed stack is not proof every amount stayed unchanged; concurrent compounds/diet/injuries; one reply has 100mg typo, not adopted.

Source context — CJC-1295 DAC half-life/sides: No symptom-resolution date, product verification or laboratory attribution; current opened body showed OP without usable replies.

Source context — CJC 1295 dac and lethargy: Testosterone co-use, no objective endpoint; replies confuse DAC with short-acting schedules; no completed-cycle follow-up; mixing details excluded.

Doses people talk about

Under-skin weekly total	Community charts name about 1–2 mg/week, including 2 mg once weekly or 1 mg twice weekly around 3–4 days apart. Opened accounts include 1 mg and 2,000 mcg weekly.
Other chart camps	Separate charts name 0.5–1 mg/week, 300–600 mcg per injection once or twice weekly, or 2–3 mg/week. One account used 400 mcg twice weekly; none establishes a safe ceiling.

Notes

SubQ: about 1–2 mg total per week in community charts. Charts describe 2 mg once weekly or 1 mg twice weekly, roughly 3–4 days apart. Opened accounts include 1 mg weekly and 2,000 mcg weekly. These are reported amounts, not a standard or safe ceiling; 1,000 mcg equals 1 mg. CJC-1295 DAC: first-dose and sleep experiences (Community discussion · Accessed 2026-09-30) · CJC 1295 DAC: low-dose book claim and week-three update (Community discussion · Accessed 2026-09-30)

Lower and higher amounts are separate camps. Other charts include 0.5–1 mg/week, 300–600 mcg per injection once or twice weekly, and higher 2–3 mg/week talk. An opened account used 400 mcg twice weekly. Another thread disputed a book-derived 100 mcg twice-weekly or daily claim; the book itself was not inspected. CJC-1295 DAC: first-dose and sleep experiences (Community discussion · Accessed 2026-09-30) · CJC 1295 DAC: low-dose book claim and week-three update (Community discussion · Accessed 2026-09-30)

Half-life, onset & duration

Felt onset	First-dose warmth and sleep changes over nights are different endpoints. Some use 2–4-week sleep/recovery checks and 6–8-week physique checks; unwanted swelling can emerge after weeks.
Felt duration	No reliable single-dose benefit window or symptom-clearance countdown. The stiff-hands account had no resolved-at date after stopping.
Half-life	Roughly a week. Formal under-skin studies estimated 5.8–8.1 days after single doses and 5.4–9.2 after repeated doses; these are clearance measurements, not guaranteed benefit duration.

Notes

First-dose warmth; sleep changes over nights in some accounts. One first-dose account described flushing at about 1 mg; another reported better sleep after two nights. These are different endpoints. Feeling nothing immediately does not establish that a product failed, and warmth does not establish that it works. CJC-1295 DAC: first-dose and sleep experiences (Community discussion · Accessed 2026-09-30)

Unwanted effects can emerge after weeks. Water retention and stiff hands appeared after a couple of weeks in one account. Community summaries describe 2–4-week sleep/recovery checks and 6–8-week physique anecdotes; these are discussion timelines, not established onset windows. CJC-1295 DAC half-life/sides (Personal report · Accessed 2026-09-30)

A reliable single-dose felt-benefit window is unknown. Accounts mainly describe repeated weekly use. Better sleep at week three does not mean one injection produced three weeks of benefit. The inspected reports provide no consistent duration for sleep, recovery or physique changes. CJC 1295 DAC: low-dose book claim and week-three update (Community discussion · Accessed 2026-09-30) · CJC-1295 DAC: first-dose and sleep experiences (Community discussion · Accessed 2026-09-30)

No established symptom-clearance countdown after stopping. The stiff-hands user posted about two weeks after stopping but supplied no resolved-at date. Existing “days to 1–2+ weeks” offset talk describes an expectation of slow fade, not a verified washout or a promise that swelling resolves then. CJC-1295 DAC half-life/sides (Personal report · Accessed 2026-09-30)

About 6–8 days, or roughly a week, is repeated by users. Both opened Reddit discussions circulate this estimate. It comes from formal long-acting CJC research, not a community measurement of a vial or person. It describes declining drug concentration, not a week of guaranteed benefits or a deadline for side effects to disappear. CJC-1295 DAC half-life/sides (Personal report · Accessed 2026-09-30) · CJC-1295 DAC: first-dose and sleep experiences (Community discussion · Accessed 2026-09-30)

Measured half-life and hormone persistence are different clocks. Teichman’s healthy-adult SubQ studies estimated 5.8–8.1 days after single doses and 5.4–9.2 days after repeated doses. GH remained elevated for at least six days; IGF-1 for 9–11 days, and through day 28 with repeated dosing. The clinical exposures differed from fixed weekly community amounts. A blood peak is not felt onset. Teichman et al. 2006: prolonged GH and IGF-I stimulation in healthy adults (Official context · Accessed 2026-09-30)

Source context — CJC-1295 DAC half-life/sides: No symptom-resolution date, product verification or laboratory attribution; current opened body showed OP without usable replies.

Source context — Teichman et al. 2006: prolonged GH and IGF-I stimulation in healthy adults: Primary paper read through a third-party mirror; small short studies, hormone endpoints, developer affiliation; not an approved consumer regimen or athletic safety study.

Cycles people discuss

Weeks to months	8–12-week blocks recur; 4–6-week checks, 12–16-week runs and continuous months also appear. One opened account planned eight weeks; another reported three months.
Break customs	About four weeks, 4–8 weeks or equal time off are competing customs. No needed break, protective cycling effect or steroid-style post-cycle treatment is established.

Notes

8–12-week blocks, with longer and shorter runs also discussed. One opened user planned eight weeks; another reported three months of weekly use. Community summaries also describe 12–16-week runs, continuous months and shorter 4–6-week reassessments. A stated plan is not a completed outcome or validated cycle. CJC 1295 DAC: low-dose book claim and week-three update (Community discussion · Accessed 2026-09-30)

Breaks range from about 4 weeks to 4–8 weeks or equal time off. These are competing community customs. Seasonal reruns, three-month-on/one-month-off marketing and desensitization concerns help explain the differences. The discussion does not establish a needed break, protective cycling effect, catch-up rule for missed doses or steroid-style post-cycle treatment.

Stacks

Ipamorelin and GHRPs	DAC is paired with daily or bedtime Ipamorelin, often 100–300 mcg per Ipamorelin administration. Older stacks use GHRP-2, GHRP-6 or Hexarelin; those amounts describe the companion, not DAC.
Recovery and hormone stacks	BPC-157/TB-500 and occasional testosterone co-use appear. Moving to Mod GRF plus a GHRP is often a switch; comparing MK-677, Sermorelin, Tesamorelin or HGH does not mean combining them.

Notes

Stacking makes attribution difficult. Solo DAC, DAC plus daily/bedtime Ipamorelin (often 100–300 mcg per Ipamorelin administration), older GHRP-2/GHRP-6/Hexarelin stacks, and BPC-157/TB-500 combinations all appear in the discussion. Hunger, sleep, recovery and laboratory changes cannot automatically be assigned to DAC. Users also compare MK-677, Sermorelin, Tesamorelin and HGH; double-GHRH stacking remains redundancy debate. CJC1295DAC experiences; hypo, lethargy, etc. (Community discussion · Accessed 2026-09-30)

Switch not stack (vs no-DAC): Many drop DAC for Mod GRF + GHRP rather than run both GHRH forms together. [community]

TRT / men’s clinic adjacency: Occasionally layered in wellness-forum protocols with testosterone replacement — confounded. [community]

Source context — CJC1295DAC experiences; hypo, lethargy, etc.: Self-described hypo lacks glucose measurements; complex co-use; board-sponsor advice is promotional/opinion, not clinical evidence; page 2 not inspected.

Watch for

Fluid, nerves and fatigue	Swelling, tight rings, numb or stiff hands, joint aches and disruptive lethargy are reported. Bedtime use was not a demonstrated remedy.
Hunger is not a glucose test	A user called hunger and lethargy hypo without measured low glucose. Headache, restless sleep and metabolic concerns also occur; another compound does not establish the cause.
Long exposure and unknown safety	Stopping may not end effects that day. Vial identity and long-term GH/IGF-1 safety remain uncertain; the saved FDA review includes an early trial death without established causation.

Notes

A “hypo” feeling is not a glucose diagnosis. An AnabolicMinds user described hunger and lethargy that differed across products. No measured low glucose was supplied. Existing cautions also include restless sleep, headache, appetite changes and metabolic concerns; neither a forum label nor adding another compound explains the cause. CJC1295DAC experiences; hypo, lethargy, etc. (Community discussion · Accessed 2026-09-30)

CJC-1295 with DAC is a long-acting peptide discussed for better sleep, recovery and body recomposition with fewer injections. Users describe better sleep, little visible change, or troublesome fluid retention and fatigue. Its long exposure is the attraction and the main practical drawback: stopping does not necessarily mean effects end that day.

Long-term safety and product identity remain uncertain. Community cautions flag GH/IGF-1 concerns with malignancy, glucose regulation, pregnancy and breastfeeding, plus unknown vial contents. FDA's 2024 review identifies no approved CJC drug and an early trial stopped after a death with unpublished data; that record does not establish causation. FDA 2024 CJC-1295-related substances review (Official context · Accessed 2026-09-30)

Source context — CJC-1295 DAC half-life/sides: No symptom-resolution date, product verification or laboratory attribution; current opened body showed OP without usable replies.

Source context — CJC 1295 dac and lethargy: Testosterone co-use, no objective endpoint; replies confuse DAC with short-acting schedules; no completed-cycle follow-up; mixing details excluded.

Source context — FDA 2024 CJC-1295-related substances review: Regulatory review includes nonclinical data and incompletely specified forms; trial-death summary cites secondary reports and does not resolve causation.

Full notes

What DAC changes

A longer-lasting signal to release growth hormone. CJC mimics growth-hormone-releasing hormone, which signals the pituitary to release GH; GH influences downstream IGF-1. DAC means Drug Affinity Complex, an attachment that binds albumin in blood and prolongs exposure. This is systemic hormone-axis stimulation, not local tendon repair. Official context
The name alone can hide two different products. Papers generally mean the long-acting DAC form. Community shorthand also calls short-acting Mod GRF 1–29 “CJC-1295.” Daily CJC/Ipamorelin blends frequently mean no-DAC. The preserved discussion describes mostly subcutaneous injections, occasional intramuscular claims and no dependable oral equivalent; none is interchangeable by milligram arithmetic. Community

What people hope to gain

Sleep is a reported benefit; physique change is less immediate. One Reddit user described better sleep after two nights. Another, using DAC with Ipamorelin and injury peptides, reported better sleep at week three but no noticeable muscle gain or major fat loss. Neither account isolates DAC or predicts someone else's response. Reddit r/Peptides Reddit r/Peptides
Recovery and convenience drive the interest. Community accounts seek less soreness, easier training, lean-mass support, skin changes or a fuller look over weeks to months. Fewer injections matter to users tired of short-acting stacks. Water weight can imitate muscle fullness; these outcomes remain reports rather than demonstrated DAC benefits. Community Reddit r/Peptides

Doses people discuss

Amounts here refer to DAC, predominantly injected beneath the skin (SubQ). Weekly totals, per-injection amounts and short-acting blend components must stay separate.

SubQ: about 1–2 mg total per week in community charts. Charts describe 2 mg once weekly or 1 mg twice weekly, roughly 3–4 days apart. Opened accounts include 1 mg weekly and 2,000 mcg weekly. These are reported amounts, not a standard or safe ceiling; 1,000 mcg equals 1 mg. Community Reddit r/Peptides Reddit r/Peptides
Lower and higher amounts are separate camps. Other charts include 0.5–1 mg/week, 300–600 mcg per injection once or twice weekly, and higher 2–3 mg/week talk. An opened account used 400 mcg twice weekly. Another thread disputed a book-derived 100 mcg twice-weekly or daily claim; the book itself was not inspected. Community Reddit r/Peptides Reddit r/Peptides

Half-life: the number circulating online

About 6–8 days, or roughly a week, is repeated by users. Both opened Reddit discussions circulate this estimate. It comes from formal long-acting CJC research, not a community measurement of a vial or person. It describes declining drug concentration, not a week of guaranteed benefits or a deadline for side effects to disappear. Personal report Reddit r/Peptides

Onset: what changes first

First-dose warmth; sleep changes over nights in some accounts. One first-dose account described flushing at about 1 mg; another reported better sleep after two nights. These are different endpoints. Feeling nothing immediately does not establish that a product failed, and warmth does not establish that it works. Reddit r/Peptides
Unwanted effects can emerge after weeks. Water retention and stiff hands appeared after a couple of weeks in one account. Community summaries describe 2–4-week sleep/recovery checks and 6–8-week physique anecdotes; these are discussion timelines, not established onset windows. Personal report Community

Duration: benefits and stopping

A reliable single-dose felt-benefit window is unknown. Accounts mainly describe repeated weekly use. Better sleep at week three does not mean one injection produced three weeks of benefit. The inspected reports provide no consistent duration for sleep, recovery or physique changes. Reddit r/Peptides Reddit r/Peptides
No established symptom-clearance countdown after stopping. The stiff-hands user posted about two weeks after stopping but supplied no resolved-at date. Existing “days to 1–2+ weeks” offset talk describes an expectation of slow fade, not a verified washout or a promise that swelling resolves then. Personal report Community

Cycles and time off

8–12-week blocks, with longer and shorter runs also discussed. One opened user planned eight weeks; another reported three months of weekly use. Community summaries also describe 12–16-week runs, continuous months and shorter 4–6-week reassessments. A stated plan is not a completed outcome or validated cycle. Community Reddit r/Peptides
Breaks range from about 4 weeks to 4–8 weeks or equal time off. These are competing community customs. Seasonal reruns, three-month-on/one-month-off marketing and desensitization concerns help explain the differences. The discussion does not establish a needed break, protective cycling effect, catch-up rule for missed doses or steroid-style post-cycle treatment. Community

What can make the tradeoff worse

Fluid retention, stiff hands and fatigue deserve their own attention. Swelling, ring tightness, numbness and joint aches can obscure perceived physique gains. An opened bodybuilding-forum user found lethargy disruptive despite believing they were leaning out; testosterone use confounded that account. Bedtime administration was not a demonstrated solution. Personal report Personal report Community
A “hypo” feeling is not a glucose diagnosis. An AnabolicMinds user described hunger and lethargy that differed across products. No measured low glucose was supplied. Existing cautions also include restless sleep, headache, appetite changes and metabolic concerns; neither a forum label nor adding another compound explains the cause. AnabolicMinds Community
Long-term safety and product identity remain uncertain. Community cautions flag GH/IGF-1 concerns with malignancy, glucose regulation, pregnancy and breastfeeding, plus unknown vial contents. FDA's 2024 review identifies no approved CJC drug and an early trial stopped after a death with unpublished data; that record does not establish causation. Community Official context

What the community experiences add

A first flush and a later benefit are different experiences. The three-week Reddit update described warmth for about 30 minutes and a pleasant feeling after it faded, while better sleep was the main noticeable benefit. That account does not make flushing a potency test. The user also had several injury peptides, diet changes and physical limitations. Reddit r/Peptides
Fewer injections versus shorter exposure. Users debate DAC convenience against Mod GRF/Ipamorelin pulses. Community comparisons repeat roughly 30-minute no-DAC half-life lore and 100–300 mcg short-acting doses, often multiple times daily. Those circulated figures do not convert to weekly DAC amounts or prove either approach superior. Community Reddit r/Peptides
Stacking makes attribution difficult. Solo DAC, DAC plus daily/bedtime Ipamorelin (often 100–300 mcg per Ipamorelin administration), older GHRP-2/GHRP-6/Hexarelin stacks, and BPC-157/TB-500 combinations all appear in the discussion. Hunger, sleep, recovery and laboratory changes cannot automatically be assigned to DAC. Users also compare MK-677, Sermorelin, Tesamorelin and HGH; double-GHRH stacking remains redundancy debate. Community AnabolicMinds
Timing rituals and labs answer different questions. Fasted or bedtime use, avoiding carb-heavy meals and choosing fixed weekdays are community habits, not proof of better results. Some track IGF-1 and fasting glucose after several weeks; a changed laboratory surrogate does not demonstrate fat loss, stronger tissue or safety. Community Community

Supporting human research, separately

Measured half-life and hormone persistence are different clocks. Teichman’s healthy-adult SubQ studies estimated 5.8–8.1 days after single doses and 5.4–9.2 days after repeated doses. GH remained elevated for at least six days; IGF-1 for 9–11 days, and through day 28 with repeated dosing. The clinical exposures differed from fixed weekly community amounts. A blood peak is not felt onset. Official context
“GH bleed” does not mean pulses vanish. Ionescu and Frohman found that GH pulses remained while trough GH and IGF-1 rose. That supports elevated background levels alongside pulses, not proof of long-term safety or physique superiority. Official context
Animal signals stay animal signals. FDA's review discusses animal injection-site toxicity and laboratory safety signals, with incomplete formulation information. These cannot establish a human adverse-event rate. The human studies measured hormones rather than athletic outcomes. Official context